Toxoplasmosis

Summary

Toxoplasmosis (MONDO:0005989) is a disease and 14 clinical trials. Top therapeutic interventions include leucovorin, pyrimethamine, and spiramycin. A subtype of coccidiosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 14

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	toxoplasmosis
Mondo ID	MONDO:0005989
EFO	EFO:0007517
MeSH	D014123
DOID	DOID:9965
ICD-10-CM	B58
ICD-11	738999268
NCIT	C3418
SNOMED CT	187192000
UMLS	C0040558
MedGen	21597
Is cancer (heuristic)	no

Also known as: Toxoplasma gondii caused disease or disorder · Toxoplasma gondii disease or disorder · Toxoplasma gondii infectious disease

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › coccidiosis › toxoplasmosis

Related subtypes (4): cyclosporiasis, cryptosporidiosis, isosporiasis, sarcocystosis

Subtypes (3): cerebral toxoplasmosis, congenital toxoplasmosis, ocular toxoplasmosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Status
Pyrimethamine	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 14.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	10
PHASE4	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00004317	PHASE4	RECRUITING	Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
NCT02011750	PHASE4	COMPLETED	Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia
NCT01479361	PHASE1	COMPLETED	Antiretroviral Drug Interaction Study in Volunteers With HIV
NCT03258762	PHASE1	COMPLETED	Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects
NCT06305468	Not specified	RECRUITING	Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis
NCT07054918	Not specified	NOT_YET_RECRUITING	Isolated Positive Toxoplasma Gondii PCR in Blood
NCT07346833	Not specified	RECRUITING	Role of Circulating MicroRNAs in Differentiating Psychological Disorders Among Women With Chronic Toxoplasmosis
NCT03932656	Not specified	WITHDRAWN	Latent Toxoplasmosis in Females With Borderline Personality Disorder
NCT03993093	Not specified	COMPLETED	Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
NCT04825600	Not specified	COMPLETED	Diagnosis of Toxoplasma Gondii Infection by Exploration of Cellular Immunity (TOXCELL)
NCT05783778	Not specified	UNKNOWN	Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris
NCT05860998	Not specified	UNKNOWN	Measuring the Prevalence of Toxoplasmosis and Its Socio-economic Consequences
NCT05963295	Not specified	UNKNOWN	Toxoplasma Gondii Infection in Both Children and Adult Patients With Hematological Malignancies
NCT07044037	Not specified	COMPLETED	Analysis of Cerebrospinal Fluid in Patients With Cerebral Toxoplasmosis at CHSD (2004-2024)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LEUCOVORIN	4	4
PYRIMETHAMINE	4	2
SPIRAMYCIN	4	1
SULFADIAZINE	4	1
CHEMBL4278112	0	1
CHEMBL4758173	0	1